T1	Modifier 25 35	Refractory
E1	Modifier:T1 Modifies:T104
T2	Or 36 38	or
E2	Or:T2 Arg:E1 Arg2:E3
T3	Modifier 39 47	relapsed
E3	Modifier:T3 Modifies:T104
T4	Condition 48 51	AML
E4	Condition:T4 Name:T104
T5	Condition 82 100	Refractory disease
E5	Condition:T5 Name:T105
T7	Eq-Comparison 120 130	at least 1
E7	Eq-Comparison:T7 Operator:T106 Value:T107
T8	Procedure 137 146	treatment
E8	Procedure:T8 Minimum-Count:E7 Temporality:E6
T9	Negation 152 154	no
E9	Negation:T9 Negates:E10
T10	Condition 155 164	remission
E10	Condition:T10 Name:T179
T11	Condition 176 192	Relapsed disease
E11	Condition:T11 Name:T109
T13	Eq-Comparison 212 222	5% or more
E13	Eq-Comparison:T13 Value:T110 Unit:T111 Operator:T112
T16	Temporal-Connection 250 255	after
E16	Temporal-Connection:T16 Arg:E12 Arg2:E17
A4	Temporal-Connection-Type-Value E16 after
T17	Condition 256 265	remission
E17	Condition:T17 Name:T15
T18	Condition 291 294	AML
E18	Condition:T18 Name:T115
T19	Condition 308 333	myelodysplastic syndromes
E19	Condition:T19 Name:T116
T20	Condition 345 349	CMML
E20	Condition:T20 Name:T117
T21	Or 351 353	or
E21	Or:T21 Arg:E20 Arg2:E22
T22	Condition 354 382	myeloproliferative neoplasms
E22	Condition:T22 Name:T118
T23	Modifier 384 393	secondary
E23	Modifier:T23 Modifies:T119
T24	Condition 394 397	AML
E24	Condition:T24 Name:T119
T25	Condition 399 405	ts-AML
E25	Condition:T25 Name:T120
T26	Observation 431 454	Circulating blast count
E26	Observation:T26 Name:T121 Eq-Comparison:E27 Temporality:E28
T27	Eq-Comparison 455 463	≤ 200/μL
E27	Eq-Comparison:T27 Operator:T122 Value:T123 Per:T114
T28	Eq-Comparison 464 478	within 10 days
E28	Eq-Comparison:T28 Operator:T124 Value:T125 Temporal-Unit:T126
T29	Temporal-Connection 479 487	prior to
E29	Temporal-Connection:T29 Arg:E28 Arg2:E30
A5	Temporal-Connection-Type-Value E29 before
T30	Eq-Comparison 488 493	first
E30	Eq-Comparison:T30 Temporal-Recency:T127
T31	Procedure 503 512	treatment
E31	Procedure:T31 Temporality:E30
T32	Drug 514 525	Hydroxyurea
E32	Drug:T32 Name:T128
T35	Observation 553 575	peripheral blast count
E35	Observation:T35 Name:T33 Eq-Comparison:E36
T36	Eq-Comparison 576 584	≤ 200/μL
E36	Eq-Comparison:T36 Operator:T129 Value:T130 Per:T34
T37	Temporal-Connection 585 590	until
E37	Temporal-Connection:T37 Arg:E32 Arg2:E38
A8	Temporal-Connection-Type-Value E37 before
T38	Eq-Comparison 595 604	first day
E38	Eq-Comparison:T38 Temporal-Recency:T181
T39	Procedure 617 626	treatment
E39	Procedure:T39 Temporality:E38
T41	Observation 669 673	ECOG
E41	Observation:T41 Name:T131 Eq-Comparison:E42
T42	Eq-Comparison 674 677	≤ 2
E42	Eq-Comparison:T42 Operator:T182 Value:T183
T43	Observation 683 713	Estimated creatinine clearance
E43	Observation:T43 Name:T132 Eq-Comparison:E45
T45	Eq-Comparison 714 725	≥ 50 mL/min
E45	Eq-Comparison:T45 Value:T134 Unit:T135 Per:T136
T46	Observation 731 734	AST
E46	Observation:T46 Name:T137 Eq-Comparison:E49
T47	And 735 738	and
E47	And:T47 Arg:E46 Arg2:E48
T48	Observation 739 742	ALT
E48	Observation:T48 Name:T138 Eq-Comparison:E49
T49	Eq-Comparison 743 754	≤ 3.0 x ULN
E49	Eq-Comparison:T49 Operator:T139 Value:T140 Unit:T44
T50	Observation 760 769	Bilirubin
E50	Observation:T50 Name:T141 Eq-Comparison:E51
T51	Eq-Comparison 770 781	≤ 3.0 x ULN
E51	Eq-Comparison:T51 Operator:T142 Value:T143 Unit:T184
T52	Eq-Comparison 807 813	Active
E52	Eq-Comparison:T52 Temporal-Period:T144
T53	Modifier 814 817	CNS
E53	Modifier:T53 Modifies:T145
T54	Condition 818 826	Leukemia
E54	Condition:T54 Name:T145 Temporality:E52
T55	Condition 839 852	HIV infection
E55	Condition:T55 Name:T146
T56	Or 853 855	or
E56	Or:T56 Arg:E55 Arg2:E60
T58	Modifier 862 873	hepatitis B
E58	Modifier:T58 Modifies:T148
T59	Or 874 876	or
E59	Or:T59 Arg:E58 Arg2:E15
T60	Condition 889 898	infection
E60	Condition:T60 Name:T148
T62	Observation 918 928	viral load
E62	Observation:T62 Name:T149 Polarity:T147
T63	Eq-Comparison 952 960	received
E63	Eq-Comparison:T63 Temporal-Period:T150
T64	Or 968 974	and/or
E64	Or:T64 Arg:T61 Arg2:T151
T66	Drug 984 998	CYP3A inducers
E66	Drug:T66 Name:T152 Temporality:E63 Dose:T61 Dose2:T151 Temporality2:E67
T67	Eq-Comparison 999 1012	within 7 days
E67	Eq-Comparison:T67 Operator:T153 Value:T154 Temporal-Unit:T155
T68	Temporal-Connection 1013 1021	prior to
E68	Temporal-Connection:T68 Arg:E67 Arg2:E69
A10	Temporal-Connection-Type-Value E68 before
T69	Eq-Comparison 1026 1036	initiation
E69	Eq-Comparison:T69 Temporal-Recency:T156
T70	Study 1040 1045	study
E70	Study:T70 Study-Of:E71
T71	Procedure 1046 1055	treatment
E71	Procedure:T71 Temporality:E69
T72	Eq-Comparison 1067 1081	received prior
E72	Eq-Comparison:T72 Temporal-Period:T157
T73	Procedure 1082 1091	radiation
E73	Procedure:T73 Name:T158 Temporality:E72 Severity:T159 Polarity:T160
T75	Modifier 1145 1150	organ
E75	Modifier:T75 Modifies:T158
T76	Condition 1180 1195	cardiac disease
E76	Condition:T76 Name:T162 Severity:T161
T77	Eq-Comparison 1202 1208	Active
E77	Eq-Comparison:T77 Temporal-Period:T163
T78	Modifier 1210 1222	uncontrolled
E78	Modifier:T78 Modifies:T165
T79	Condition 1231 1240	infection
E79	Condition:T79 Name:T165 Severity:T164 Temporality:E77
T80	Other 1252 1257	other
E80	Other:T80 Is-Other:E82
T81	Modifier 1262 1269	myeloid
E81	Modifier:T81 
T82	Condition 1270 1280	malignancy
E82	Condition:T82 Name:T166 Temporality:E83
T83	Eq-Comparison 1281 1295	within 2 years
E83	Eq-Comparison:T83 Operator:T167 Value:T168 Temporal-Unit:T169
T84	Temporal-Connection 1296 1298	of
E84	Temporal-Connection:T84 Arg:E83 Arg2:E85
A11	Temporal-Connection-Type-Value E84 before
T85	Study 1299 1304	entry
E85	Study:T85 
T86	Condition 1329 1349	Psychiatric disorder
E86	Condition:T86 Name:T170
T87	Assertion 1355 1360	would
E87	Assertion:T87 Asserted:E88
A12	Assertion-Type-Value E87 hypothetical
T88	Negation 1361 1369	preclude
E88	Negation:T88 Negates:E89
T89	Study 1370 1375	study
E89	Study:T89 
T90	Eq-Comparison 1395 1403	Previous
E90	Eq-Comparison:T90 Temporal-Period:T171
T91	Modifier 1404 1409	solid
E91	Modifier:T91 Modifies:T172
T92	Procedure 1410 1426	organ transplant
E92	Procedure:T92 Name:T172 Temporality:E90
T93	Eq-Comparison 1428 1433	prior
E93	Eq-Comparison:T93 Temporal-Period:T173
T94	Procedure 1434 1443	treatment
E94	Procedure:T94 Temporality:E93
T95	Procedure 1449 1452	SCT
E95	Procedure:T95 Name:T174
T96	And 1464 1467	but
E96	And:T96 Arg:E95 Arg2:E97
T97	Negation 1468 1471	not
E97	Negation:T97 Negates:E98
T98	Condition 1487 1491	GVHD
E98	Condition:T98 Name:T175
T99	Or 1492 1494	or
E99	Or:T99 Arg:E98 Arg2:E101
T100	Eq-Comparison 1504 1513	receiving
E100	Eq-Comparison:T100 Temporal-Period:T176
T101	Procedure 1514 1531	immunosuppression
E101	Procedure:T101 Name:T177 Temporality:E100
T102	Or 1531 1532	/
E102	Or:T102 Arg:E101 Arg2:E103
T103	Procedure 1532 1544	GVHD therapy
E103	Procedure:T103 Name:T178 Temporality:E100
T104	Condition-Name 48 51	AML
T105	Condition-Name 82 100	Refractory disease
T106	Eq-Operator 120 128	at least
A13	Eq-Operator-Value T106 GTEQ
T107	Eq-Value 129 130	1
T108	Eq-Temporal-Period 131 136	prior
A14	Eq-Temporal-Period-Value T108 past
T109	Condition-Name 176 192	Relapsed disease
T110	Eq-Value 212 213	5
T111	Eq-Unit 213 214	%
T112	Eq-Operator 215 222	or more
A15	Eq-Operator-Value T112 GTEQ
T115	Condition-Name 291 294	AML
T116	Condition-Name 308 333	myelodysplastic syndromes
T117	Condition-Name 345 349	CMML
T118	Condition-Name 354 382	myeloproliferative neoplasms
T119	Condition-Name 394 397	AML
T120	Condition-Name 399 405	ts-AML
T121	Observation-Name 431 454	Circulating blast count
A17	Observation-Type-Value T121 lab
T122	Eq-Operator 455 456	≤
A18	Eq-Operator-Value T122 LTEQ
T123	Eq-Value 457 460	200
T124	Eq-Operator 464 470	within
A19	Eq-Operator-Value T124 LTEQ
T125	Eq-Value 471 473	10
T126	Eq-Temporal-Unit 474 478	days
A20	Eq-Temporal-Unit-Value T126 day
T127	Eq-Temporal-Recency 488 493	first
A21	Eq-Temporal-Recency-Value T127 first-time
T128	Drug-Name 514 525	Hydroxyurea
T129	Eq-Operator 576 577	≤
A22	Eq-Operator-Value T129 LTEQ
T130	Eq-Value 578 581	200
T131	Observation-Name 669 673	ECOG
T132	Observation-Name 683 713	Estimated creatinine clearance
A23	Observation-Type-Value T132 lab
T133	Eq-Operator 714 715	≥
A24	Eq-Operator-Value T133 GTEQ
T134	Eq-Value 716 718	50
T135	Eq-Unit 719 721	mL
T136	Eq-Temporal-Unit 722 725	min
A25	Eq-Temporal-Unit-Value T136 minute
T137	Observation-Name 731 734	AST
A26	Observation-Type-Value T137 lab
T138	Observation-Name 739 742	ALT
A27	Observation-Type-Value T138 lab
T139	Eq-Operator 743 744	≤
A28	Eq-Operator-Value T139 LTEQ
T140	Eq-Value 745 748	3.0
T141	Observation-Name 760 769	Bilirubin
A29	Observation-Type-Value T141 lab
T142	Eq-Operator 770 771	≤
A30	Eq-Operator-Value T142 LTEQ
T143	Eq-Value 772 775	3.0
T144	Eq-Temporal-Period 807 813	Active
A31	Eq-Temporal-Period-Value T144 present
T145	Condition-Name 818 826	Leukemia
T146	Condition-Name 839 852	HIV infection
T148	Condition-Name 889 898	infection
T149	Observation-Name 918 928	viral load
A32	Observation-Type-Value T149 lab
T150	Eq-Temporal-Period 952 960	received
A33	Eq-Temporal-Period-Value T150 past
T151	Polarity 975 983	moderate
T152	Drug-Name 984 998	CYP3A inducers
T153	Eq-Operator 999 1005	within
A35	Eq-Operator-Value T153 LTEQ
T154	Eq-Value 1006 1007	7
T155	Eq-Temporal-Unit 1008 1012	days
A36	Eq-Temporal-Unit-Value T155 day
T156	Eq-Temporal-Recency 1026 1036	initiation
A37	Eq-Temporal-Recency-Value T156 first-time
T157	Eq-Temporal-Period 1067 1081	received prior
A38	Eq-Temporal-Period-Value T157 past
T158	Procedure-Name 1082 1091	radiation
T159	Severity 1129 1137	critical
A39	Severity-Value T159 severe
T160	Polarity 1138 1144	normal
A40	Polarity-Value T160 normal
T161	Severity 1168 1179	significant
A41	Severity-Value T161 severe
T162	Condition-Name 1180 1195	cardiac disease
T163	Eq-Temporal-Period 1202 1208	Active
A42	Eq-Temporal-Period-Value T163 present
T164	Severity 1223 1230	serious
A43	Severity-Value T164 severe
T165	Condition-Name 1231 1240	infection
T166	Condition-Name 1270 1280	malignancy
T167	Eq-Operator 1281 1287	within
A44	Eq-Operator-Value T167 LTEQ
T168	Eq-Value 1288 1289	2
T169	Eq-Temporal-Unit 1290 1295	years
A45	Eq-Temporal-Unit-Value T169 year
T170	Condition-Name 1329 1349	Psychiatric disorder
T171	Eq-Temporal-Period 1395 1403	Previous
A46	Eq-Temporal-Period-Value T171 past
T172	Procedure-Name 1410 1426	organ transplant
T173	Eq-Temporal-Period 1428 1433	prior
A47	Eq-Temporal-Period-Value T173 past
T174	Procedure-Name 1449 1452	SCT
T175	Condition-Name 1487 1491	GVHD
T176	Eq-Temporal-Period 1504 1513	receiving
A48	Eq-Temporal-Period-Value T176 present
T177	Procedure-Name 1514 1531	immunosuppression
T178	Procedure-Name 1532 1544	GVHD therapy
T6	Eq-Comparison 131 136	prior
E6	Eq-Comparison:T6 Temporal-Period:T108
T179	Condition-Name 155 164	remission
T180	And 147 151	with
E104	And:T180 Arg:E8 Arg2:E9
R1	Equivalent-To Arg1:E8 Arg2:E5	
T12	Observation 223 244	blasts in bone marrow
E12	Observation:T12 Name:T14 Specimen:T113 Eq-Comparison:E13
T14	Observation-Name 223 229	blasts
A1	Observation-Type-Value T14 lab
T113	Observation-Specimen 233 244	bone marrow
T15	Condition-Name 256 265	remission
R2	Equivalent-To Arg1:E12 Arg2:E11	
R3	Caused-By Arg1:E18 Arg2:E19	
R4	Abbrev-Of Arg1:E20 Arg2:E19	
R5	Caused-By Arg1:E18 Arg2:E22	
R6	Abbrev-Of Arg1:E24 Arg2:E22	
R7	Abbrev-Of Arg1:E25 Arg2:E22	
T114	Eq-Unit 461 463	μL
T33	Observation-Name 553 575	peripheral blast count
A2	Observation-Type-Value T33 lab
T34	Eq-Unit 582 584	μL
R8	Caused-By Arg1:E35 Arg2:E32	
T181	Eq-Temporal-Recency 595 604	first day
A3	Eq-Temporal-Recency-Value T181 first-time
T40	Assertion 526 540	should be used
E14	Assertion:T40 Asserted:E32
A6	Assertion-Type-Value E14 hypothetical
T182	Eq-Operator 674 675	≤
A7	Eq-Operator-Value T182 LTEQ
T183	Eq-Value 676 677	2
T44	Eq-Unit 751 754	ULN
T184	Eq-Unit 778 781	ULN
T57	Modifier 877 888	hepatitis C
E15	Modifier:T57 Modifies:T148
T147	Polarity 907 917	detectable
A9	Polarity-Value T147 positive
R9	Found-By Arg1:E60 Arg2:E62	
R10	Found-By Arg1:E55 Arg2:E62	
T61	Polarity 961 967	strong
A49	Polarity-Value T151 medium
A16	Polarity-Value T61 high
T65	Modifier 1095 1121	maximally tolerated levels
E33	Modifier:T65 Modifies:T158
T74	Negation 1258 1261	non
E34	Negation:T74 Negates:E81
R11	Caused-By Arg1:E88 Arg2:E86	
R12	Using Arg1:E94 Arg2:E95	
